COX-2 overexpression induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 537-542

  Okamura, Hiroko ^a   Fujiwara, Hitoshi ^a   Umehara, Seiji ^a   Okamura, Shinichi ^a   Todo, Momoko ^a   Furutani, Akinobu ^a   Yoneda, Masayuki ^a   Shiozaki, Atsushi ^a   Komatsu, Shuhei ^a   Kubota, Takeshi ^a   Ichikawa, Daisuke ^a   Okamoto, Kazuma ^a   Ochiai, Toshiya ^a   Sakakura, Chouhei ^a   Takahashi, Yoshitaka ^b   Yoshimoto, Tanihiro ^c   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OKAYAMA PREFECTURAL UNIVERSITY   (Japan)

^c KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Chemosensitivity; Cisplatin; COX 2; Esophageal carcinoma; Gene transfer; TE13 cells

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; FLUOROURACIL; PROSTAGLANDIN E2; PROTEIN BCL 2;

ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ESOPHAGUS CARCINOMA; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLOOXYGENASE 2; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENE TRANSFER TECHNIQUES; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; UP-REGULATION;

EID: 84875903503     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003.
2. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007.
3. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K and Fukuda H: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19: 68-74, 2012.
4. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
5. Dempke W, Rie C, Grothey A and Schmoll HJ: Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127: 411-417, 2001.
6. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H and Monden M: Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 6: 1229-1238, 2000.
7. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO and Scambia G: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13: 1205-1211, 2002.
8. Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, Park HC, Suh CO, Park TK and Kim BS: Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95: 531-539, 2002.
9. Wülfing C, Eltze E, von Struensee D, Wülfing P, Hertle L and Piechota H: Cyclooxygenase-2 expression in bladder cancer: Correlation with poor outcome after chemotherapy. Eur Urol 45: 46-52, 2004.
10. Anai S, Tanaka M, Shiverick KT, Kim W, Takada S, Boehlein S, Goodison S, Mizokami A and Rosser CJ: Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. J Urol 177: 1913-1917, 2007.
11. Huang WZ, Fu JH, Wang DK, Hu Y, Liu MZ, Yang H, Feng YF, Zheng B, Wang G, Luo KJ, Wen J and Rong TH: Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients. Dis Esophagus 21: 679-684, 2008.
12. Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y and Matsubara H: COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18: 2946-2951, 2011.
13. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, Ling FC, Dienes HP, Bollschweiler E, Moenig S, Mueller RP, Hoelscher AH and Schneider PM: High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11: 8341-8347, 2005.
14. Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y, Hagiwara A, Mitsufuji S, Okazaki Y, Hayashizaki Y and Yamagishi H: Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer 91: 1543-1550, 2004.
15. Yoshimoto T, Takahashi Y, Kinoshita T, Sakashita T, Inoue H and Tanabe T: Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. Adv Exp Med Biol 507: 403-407, 2002.
16. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schrör K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59: 198-204, 1999.
17. Souza RF, Shewmake K, Beer DG, Cryer B and Spechler SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60: 5767-5772, 2000.
18. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A, Wu M, Zhan Q and Liu Z: Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 27: 1214-1221, 2006.
19. Deasy BM, O'Sullivan-Coyne G, O'Donovan TR, McKenna SL and O'Sullivan GC: Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms. Cancer Lett 256: 246-258, 2007.
20. Liu JF, Zhang SW, Jamieson GG, Zhu GJ, Wu TC, Zhu TN, Shan BE and Drew PA: The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. Int J Cancer 122: 1639-1644, 2008.
21. Liu JF, Zhu GJ, Jamieson GG, Wu TC, Zhu TN, Shan BE and Drew PA: NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2. Cancer Invest 27: 17-23, 2009.
22. Mehar A, Macanas-Pirard P, Mizokami A, Takahashi Y, Kass GE and Coley HM: The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J Pharmacol Exp Ther 324: 1181-1187, 2008.
23. Tjiu JW, Liao YH, Lin SJ, Huang YL, Tsai WL, Chu CY, Kuo ML and Jee SH: Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol 126: 1143-1151, 2006.
24. Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R and Merlin JL: Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 83: 1380-1386, 2000.